Hotgen(SH:688068)2026-01-16 08:45Financial Projections - The company expects 2025 annual revenue to be between 400 million and 420 million yuan, representing a year-on-year decrease of 17.79% to 21.71% compared to 2024[3]. - The projected net loss attributable to the parent company for 2025 is between 210 million and 230 million yuan, an increase in loss of 9.94% to 20.42% compared to the previous year[3]. - The expected net loss attributable to the parent company after deducting non-recurring gains and losses is between 250 million and 270 million yuan[3]. - In 2024, the company reported annual revenue of 510.9 million yuan and a net loss of 191 million yuan[4]. - The performance forecast is based on preliminary calculations by the finance department and has not been audited by an accounting firm[7]. - Investors are advised that the forecast data is preliminary and the final audited financial data will be disclosed in the 2025 annual report[8]. Performance Decline Factors - The decline in performance is primarily due to industry policy impacts, including price reductions and decreased demand in the in vitro diagnostic sector, as well as adjustments in tax policies affecting gross margins[6]. R&D Investments - The company increased its investment in the joint venture ShunJing Pharmaceutical, which has become a subsidiary, leading to significant R&D expense increases[6]. - The company’s joint ventures, including YaoJing Gene and ZhiYuan Bio, have intensified R&D investments in innovative drugs, contributing to increased investment losses[6].